PCI Synthesis, Inc. (www.pcisynthesis.com), a manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products, announced that it is a sponsor and steering committee member of the New England CRO/CMO Council (www.necrocmo.com), along with Averica Discovery Services, Organix TGA Sciences, Inc. and CE3.
The non-profit New England CRO/CMO Council is open to contract research organizations (CROs) and contract manufacturing organizations (CMOs) operating in and around Boston, the nation’s largest life sciences cluster. The Council is designed to market the cluster and to provide the broader BioPharma community with a means of accessing local CRO’s, CMOs and other suppliers to meet their current and future outsourcing requirements.
The N.E. CRO/CMO Council will work with life science-related government organizations and trade groups to increase their understanding of the CRO/CMO community and the value of outsourcing locally.
“More than 75 CROs and CMOs operate within 2 1/2 hours of Boston, making this region the largest cluster of its kind. We represent every phase of outsourcing, which provides another reason this region is ideal for drug development,” said Edward Price, president of PCI Synthesis. “We started the N.E. CRO/CMO Council to give a voice to local companies working to raise awareness in the larger community and in other regions. Given that it takes longer and costs more to develop drugs, the Council is also looking at ways its members can streamline processes, collaborate more effectively, and help our clients get their drugs ready for FDA approval and then to manufacture those drugs on a large scale-basis.”
The first event, held at the Trade Center in Woburn, MA, on Dec. 10th, presented the council’s goals to representatives from nearly 35 local CROs/CMOs as well as industry consultants and other interested individuals. Craig Muir, Partner and CTO of Third Rock Ventures, discussed outsourcing approaches utilized by the firm as well as partnerships currently in place. Dinah Sah, Ph.D., VP of Neuroscience at Voyager Therapeutics, Inc. a portfolio company of Third Rock Ventures, presented a case study of a current relationship with a local provider. Attendees were able to discuss various approaches with the speakers and network with other service providers. The next meeting will be scheduled in March, 2015.
Organizations interested in membership can click http://necrocmo.com/membership.
About PCI Synthesis
PCI Synthesis is a 16-year-old custom chemical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products. A contract manufacturing organization (CMO), PCI provides emerging and mid-sized pharmaceutical companies access to the expertise needed to develop and manufacture complex small molecules and APIs used in generic pharmaceuticals. To learn more about PCI Synthesis, its proprietary NCE development activities and process R&D capabilities please visit www.pcisynthesis.com.